sucrose has been researched along with Hyperphosphatemia in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (66.67) | 24.3611 |
| 2020's | 12 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ketteler, M; Sprague, SM | 1 |
| Araujo, R; Bancu, I; Bonal, J; Graterol, F; Merino-Ribas, A; Noguera-Julian, M; Paredes, R; Sampaio-Maia, B; Vergara, A | 1 |
| Coyne, DW; Kalantar-Zadeh, K; Ramos, R; Sprague, SM; Vervloet, M | 1 |
| Andrews, ES; Kendrick, J; Perez, L; Ramirez-Renteria, L; Reddin, R; Teitelbaum, I; Wilson, G; You, Z | 1 |
| Faitatzidou, D; Lioulios, G; Minasidis, I; Papagianni, A; Sampani, E; Sarafidis, PA; Stangou, M; Tsouchnikas, I; Vainas, A | 1 |
| Hirai, K; Hoshino, T; Ito, K; Kitano, T; Minato, S; Miyazawa, H; Morishita, Y; Ookawara, S; Shindo, M; Ueda, Y | 1 |
| Covic, AC; Floege, J; Ketteler, M; Perrin, A; Rastogi, A; Sprague, SM; Walpen, S | 1 |
| Abitbol, CL; Ahn, SY; Balgradean, M; Enoiu, M; Fathallah-Shaykh, S; Fila, M; Greenbaum, LA; Jankauskiene, A; Jeck, N; Klaus, G; Nelson, R; Paredes, A; Perrin, A; Stoica, C; Swinford, RD; Wickman, L | 1 |
| Arens, HJ; Chazot, C; Di Benedetto, A; Ferreira, A; Feuersenger, A; Gurevich, K; Ramos, R; Stuard, S; Walpen, S; Wolf, M | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Li, W; Liao, X; Ou, J; Rao, J; Xue, C; Zhu, Y | 1 |
| Fujino, T; Kaburagi, N; Morimoto, K; Oya, M; Takemitsu, TY; Yamashita, N; Yoshida, T | 1 |
| Covic, AC; Floege, J; Ketteler, M; Lisk, LJ; Mann, J; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM | 1 |
| Akizawa, T; Fukagawa, M; Koiwa, F; Yokoyama, K | 1 |
| Bataille, P; Daroux, M; Delattre, V | 1 |
| Anderson, L; Coyne, DW; Ficociello, LH; Kossmann, RJ; Maddux, FW; Mullon, C; Ofsthun, NJ; Parameswaran, V; Sprague, SM; Vemula, S | 1 |
| Hayashi, H; Ichie, T; Sugiura, Y; Sugiyama, T; Suzuki, D | 1 |
| Anderson, L; Coyne, DW; Ficociello, LH; Kalantar-Zadeh, K; Kossmann, RJ; Kwoh, C; Mullon, C; Ofsthun, NJ; Parameswaran, V | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Teramukai, S; Tsujimoto, Y | 1 |
| Covic, AC; Floege, J; Ketteler, M; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM; Walpen, S | 1 |
| Floege, J; Sprague, SM | 1 |
| Alfieri, C; Cozzolino, M; Gallieni, M; Malberti, F; Mazzaferro, S; Messa, P; Russo, D | 1 |
| Chazot, C; Fadel, B; Jean, G; Kareche, M; Puyoo, O | 1 |
| Davis, S; Ficociello, LH; Kalantar-Zadeh, K; Kendrick, J; Kossmann, RJ; Mullon, C; Ofsthun, NJ; Parameswaran, V | 1 |
| Al-Makki, A; Bousher, A; Shepler, B; Sutton, J | 1 |
| Cozzolino, M; Funk, F; Phan, O; Rakov, V; Teitelbaum, I | 1 |
| Chong, EM; Covic, AC; Floege, J; Gaillard, S; Ketteler, M; Lisk, LJ; Mann, JF; Rastogi, A; Spinowitz, B; Sprague, SM | 1 |
| Greig, SL; Plosker, GL | 1 |
| Lederer, SR; Schmid, H | 1 |
| Ademi, Z; Blank, PR; Braunhofer, PG; Gutzwiller, FS; Pfeil, AM; Schwenkglenks, M; Szucs, TD | 1 |
| Jang, SM; Pai, AB; Wegrzyn, N | 1 |
| Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S | 1 |
| Floege, J | 1 |
| Covic, AC; Floege, J; Ketteler, M; Lisk, L; Rakov, V; Rastogi, A; Sprague, SM | 1 |
| Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM | 1 |
| Akizawa, T; Fukagawa, M; Koiwa, F; Terao, A; Yokoyama, K | 1 |
11 review(s) available for sucrose and Hyperphosphatemia
| Article | Year |
|---|---|
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2021 |
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Phosphorus; Prospective Studies; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Sucrose | 2022 |
Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Topics: Anemia; Carbonates; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Magnesium; Randomized Controlled Trials as Topic; Renal Dialysis; Starch; Sucrose; Treatment Outcome | 2021 |
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Topics: Chelating Agents; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Government Regulation; Humans; Hyperphosphatemia; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; Treatment Outcome | 2018 |
[Hyperphosphatemia in dialysis: which binder?]
Topics: Chelating Agents; Chelation Therapy; Cohort Studies; Drug Combinations; Ferric Compounds; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Multicenter Studies as Topic; Patient Compliance; Phosphates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose | 2018 |
A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Topics: Chelating Agents; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; United States | 2014 |
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Topics: Animals; Chelating Agents; Disease Models, Animal; Dogs; Drug Combinations; Ferric Compounds; Gastrointestinal Absorption; Humans; Hyperphosphatemia; Kidney; Phosphates; Rats; Renal Insufficiency, Chronic; Risk Assessment; Sucrose; Uremia; Vascular Calcification | 2014 |
Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2015 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Topics: Animals; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Medication Adherence; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Phosphate binders in chronic kidney disease: a systematic review of recent data.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
12 trial(s) available for sucrose and Hyperphosphatemia
| Article | Year |
|---|---|
Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.
Topics: Acetates; Calcium Compounds; Drug Combinations; Ferric Compounds; Gastrointestinal Microbiome; Humans; Hyperphosphatemia; Pilot Projects; Renal Dialysis; RNA, Ribosomal, 16S; Sucrose | 2022 |
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
Topics: Adult; Age Factors; Aged; Calcimimetic Agents; Chelating Agents; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Vitamin D | 2020 |
Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
Topics: Adolescent; Child; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2021 |
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Topics: Adult; Aged; Combined Modality Therapy; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Peritoneal Dialysis; Phosphates; Sucrose; Treatment Outcome | 2017 |
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
Topics: Aged; Asian People; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sucrose; Treatment Outcome | 2017 |
Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
Topics: Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose | 2018 |
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Topics: Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sevelamer; Sucrose; Time Factors; Treatment Outcome | 2019 |
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Phosphorus; Prognosis; Renal Dialysis; Sucrose; Time Factors | 2015 |
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Prognosis; Renal Dialysis; Sucrose | 2017 |
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Biomarkers, Pharmacological; Bone Density Conservation Agents; Chelating Agents; Drug Combinations; Drug Interactions; Ergocalciferols; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
Topics: Administration, Oral; Aged; Biomarkers; Calcium; Chelating Agents; Drug Administration Schedule; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Tablets; Time Factors; Treatment Outcome | 2017 |
13 other study(ies) available for sucrose and Hyperphosphatemia
| Article | Year |
|---|---|
A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
Topics: Adult; Aged; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Hypoalbuminemia; Middle Aged; Nutritional Status; Peritoneal Dialysis; Phosphates; Phosphorus; Pilot Projects; Prospective Studies; Serum Albumin; Sucrose | 2022 |
Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
Topics: Aged; Aged, 80 and over; Anemia; Biomarkers; Drug Combinations; Female; Ferric Compounds; Ferritins; Humans; Hyperphosphatemia; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose | 2020 |
Eosinophilic peritonitis induced by sucroferric oxyhydroxide.
Topics: Drug Combinations; Eosinophilia; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Sucrose | 2020 |
The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Topics: Aged; Chelating Agents; Databases, Factual; Drug Combinations; Europe; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose | 2020 |
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Renal Dialysis; Retrospective Studies; Sucrose | 2022 |
[Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?]
Topics: Chelating Agents; Drug Combinations; Evidence-Based Medicine; Ferric Compounds; Guidelines as Topic; Humans; Hyperphosphatemia; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Sucrose; Treatment Outcome | 2017 |
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Sucrose | 2017 |
Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Topics: Aged; Chelating Agents; Constipation; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Phosphorus; Renal Dialysis; Sucrose; Time Factors | 2017 |
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Phosphorus; Retrospective Studies; Sucrose | 2018 |
[Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].
Topics: Aged; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Ferritins; France; Humans; Hyperphosphatemia; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Sucrose | 2019 |
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Topics: Adult; Aged; Chelating Agents; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Renal Dialysis; Renal Insufficiency; Sucrose; Time Factors; Treatment Outcome | 2019 |
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Topics: Cost-Benefit Analysis; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Markov Chains; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Renal Dialysis; Scotland; Sevelamer; Sucrose | 2015 |
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose | 2016 |